A practical reference on c-Met: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Since aseptic packages contain different layers of plastic and aluminium in addition to raw paper, they cannot be recycled as "normal" paper waste, but need to go to special recycling units for separation of the different materials. As a result, Tetra Pak cannot be put in recycling or compost bins. Recycled Tetra Paks may be used in producing polythene-based products and construction material, the third largest contributor to carbon footprint. Tetra Pak has operated limited recycling since the mid-1980s, introducing a recycling program for its containers in Canada as early as 1990. In 2000, Tetra Pak invested 20 million baht (€500,000) in the first recycling plant for aseptic packages in Thailand. Recycling aseptic packages has been one of Tetra Pak's challenges. Once separated, the aseptic carton yields aluminum and pure paraffin, which can be used in industry. Even without separating the carton materials, however, the aseptic carton can be reused, for example, in engineering equipment. In 2010, 30 billion used Tetra Pak cartons were recycled, doubling since 2002. The company aims to double the recycling rate within the next ten years, something that will require the engagement of the entire recycling chain. As of 2011, 20 percent of Tetra Pak cartons are recycled globally, with countries like Belgium, Germany, Spain, and Norway showing local recycling rates of over 50 percent.
== Preservation of microbiology cultures == Bacteria and fungi can be kept short-term (months to about a year, depending) refrigerated, however, cell division and metabolism is not completely arrested and thus is not an optimal option for long-term storage (years) or to preserve cultures genetically or phenotypically, as cell divisions can lead to mutations or sub-culturing can cause phenotypic changes. A preferred option, species-dependent, is cryopreservation. Nematode worms are the only multicellular eukaryotes that have been shown to survive cryopreservation.
Times have changed, however. Youth has begun to write its own rules and by the 1970s the conventions of the rugby community had begun to look a little creaky, its formalities became a bore. The cleavage was brought into sharp relief by the tragic failure of rugby to come to grips with the problem of racism in Southern Africa. The emerging reputation of the rugby player throughout the Anglo-Saxon world as an outdated, boorish oaf – a reputation derived as much from the insensitivities of the rugby community as from the intolerance of the younger generation - was given a new dimension by the quarrels over apartheid in sport. Rightly or wrongly, it has dealt the image of rugby a vicious blow, one from which it may never really recover. South Africa has now been exposed for what it really is, a malignant cancer in the corpus of rugby which has long called for the surgeon's knife. Yet the rugby community - most notably in New Zealand - still remains fatally hesitant when it comes to acting as doctor. But there were criticisms of the behaviour of some of the protesters too. Bill McLaren thought apartheid was "unacceptable", but:
sequencing The determination of the order or sequence of nucleotides in a nucleic acid molecule, or of amino acids in a peptide, by any means. Sequences are usually written as a linear string of letters which conveniently summarizes much of the atomic-level structure of the molecule.
As Louisiana treasurer, Kennedy defended his choice to invest state money in Israeli bonds, writing, "Here’s how the U.S. Secretary of State’s Office sums up our nation's relationship with Israel: 'The United States was the first country to recognize Israel as a state in 1948. Since then, Israel has become, and remains, America's most reliable partner in the Middle East. Israel and the United States are bound closely by historic and cultural ties as well as by mutual interests.' That—along with Israel Bonds' solid track record—is good enough for me.” In April 2018, Kennedy was one of eight Republican senators to sign a letter to United States Secretary of the Treasury Steve Mnuchin and acting Secretary of State John Sullivan expressing "deep concern" over a United Nations report exposing "North Korean sanctions evasion involving Russia and China" and asserting that the findings "demonstrate an elaborate and alarming military-venture between rogue, tyrannical states to avoid United States and international sanctions and inflict terror and death upon thousands of innocent people" while calling it "imperative that the United States provides a swift and appropriate response to the continued use of chemical weapons used by Syrian President Bashar al-Assad and his forces, and works to address the shortcomings in sanctions enforcement." In January 2019, Kennedy was one of 11 Republican senators to vote to advance legislation intended to block Trump's intent to lift sanctions against three Russian companies.
Sources: en.wikipedia.org
==== Newborns ==== 60–90% of male and female newborns may show breast development at birth or in the first weeks of life. During pregnancy, the placenta converts the androgenic hormones dehydroepiandrosterone (DHEA) and DHEA sulfate to the estrogenic hormones estrone and estradiol, respectively; after the placenta produces these estrogens, they are transferred into the baby's circulation, thereby leading to temporary gynecomastia in the baby. In some infants, neonatal milk (also known as "witch's milk") can leak from the nipples. The temporary gynecomastia seen in newborn babies usually resolves after two or three weeks.
Merocrine glands – cells secrete their substances by exocytosis. (e.g. mucous and serous glands; also called "eccrine", e.g. major sweat glands of humans, goblet cells, salivary gland, tear gland and intestinal glands) Apocrine glands – a portion of the secreting cell's body is lost during secretion. The term Apocrine gland is often used to refer to the apocrine sweat glands, however it is thought that apocrine sweat glands may not be true apocrine glands as they may not use the apocrine method of secretion. (e.g. mammary gland, sweat gland of arm pit, pubic region, skin around anus, lips and nipples) Holocrine glands – the entire cell disintegrates to secrete its substances. (e.g. sebaceous glands: meibomian and zeis glands) Exocrine glands can further be categorized by their product:
== Examples == An example of an isozyme is glucokinase, a variant of hexokinase which is not inhibited by glucose 6-phosphate. Its different regulatory features and lower affinity for glucose (compared to other hexokinases), allow it to serve different functions in cells of specific organs, such as control of insulin release by the beta cells of the pancreas, or initiation of glycogen synthesis by liver cells. Both these processes must only occur when glucose is abundant.
=== Early history === Saints were recognised by popular veneration acclamation until the 12th century. After controversial cases, Pope Alexander III in 1170 required all candidates for beatification to be approved by the Holy See. The papacy took total authority over the process in the 17th century.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.